INHIBITION OF ANGIOTENSIN CONVERTING ENZYME BY RAMIPRIL IN SERUM AND TISSUE OF MAN

被引:33
作者
ERMAN, A
WINKLER, J
CHENGAL, B
RABINOV, M
ZELYKOVSKI, A
TADJER, S
SHMUELI, J
LEVI, E
AKBARY, A
ROSENFELD, JB
机构
[1] BEILINSON MED CTR, INST NEPHROL & HYPERTENS, IL-49100 PETAH TIQWA, ISRAEL
[2] BEILINSON MED CTR, DEPT VASC SURG, IL-49100 PETAH TIQWA, ISRAEL
[3] BEILINSON MED CTR, DEPT THORAC SURG, IL-49100 PETAH TIQWA, ISRAEL
[4] BEILINSON MED CTR, DEPT CARDIOVASC SURG, IL-49100 PETAH TIQWA, ISRAEL
[5] BEILINSON MED CTR, DEPT UROL, IL-49100 PETAH TIQWA, ISRAEL
[6] BEILINSON MED CTR, DEPT ANESTHESIOL, IL-49100 PETAH TIQWA, ISRAEL
[7] TEL AVIV UNIV, SACKLER SCH MED, TEL AVIV, ISRAEL
[8] HOECHST AG, CLIN RES DEPT, W-6230 FRANKFURT 80, GERMANY
关键词
RAMIPRIL; ANGIOTENSIN CONVERTING ENZYME; PLASMA RENIN ACTIVITY; ANGIOTENSIN; HUMAN TISSUE; HEART; KIDNEY; ARTERY; VEIN;
D O I
10.1097/00004872-199111000-00012
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Studies in animal models have indicated that ramipril is a potent inhibitor of angiotensin converting enzyme (ACE) in serum and tissue. In our study, the normal range of ACE activity and the inhibitory effect of short-term oral administration of ramipril on ACE activity in human serum and tissue samples of renal cortex, heart and blood vessels were determined. ACE activity in the renal cortex (125.2 +/- 11.5 nmol/mg per min) was > 600 times that of the heart (0.20 +/- 0.01 nmol/mg per min), > 500 times that of the veins (0.23 +/- 0.09 nmol/mg per min) and > 150 times that of the arteries (0.80 +/- 0.23 nmol/mg per min). ACE activity in the renal cortex and arteries 2 h after last dosing was almost completely inhibited by ramipril whereas ACE activity in the veins and heart was inhibited to a lesser extent. Our results demonstrate in man, for the first time, an inhibition of tissue ACE following short-term oral treatment with an ACE inhibitor.
引用
收藏
页码:1057 / 1062
页数:6
相关论文
共 19 条
[1]   HIGH-AFFINITY BINDING OF RAMIPRILAT ON ISOLATED HUMAN GLOMERULI [J].
ALBUS, U ;
KRESS, I ;
LINZ, W ;
VASMANT, D ;
DELARUE, F ;
SRAER, JD .
BIOCHEMICAL PHARMACOLOGY, 1988, 37 (24) :4679-4684
[2]  
BRUNNER HR, 1983, HYPERTENSION ANGIOTE, P193
[3]  
Bunning P, 1987, J Cardiovasc Pharmacol, V10 Suppl 7, pS31
[4]   CIRCULATING AND TISSUE ANGIOTENSIN SYSTEMS [J].
CAMPBELL, DJ .
JOURNAL OF CLINICAL INVESTIGATION, 1987, 79 (01) :1-6
[5]  
COHEN ML, 1982, J PHARMACOL EXP THER, V220, P63
[6]   COMPARISONS INVITRO, EXVIVO, AND INVIVO OF THE ACTIONS OF 7 STRUCTURALLY DIVERSE INHIBITORS OF ANGIOTENSIN CONVERTING ENZYME (ACE) [J].
CUSHMAN, DW ;
WANG, FL ;
FUNG, WC ;
GROVER, GJ ;
HARVEY, CM ;
SCALESE, RJ ;
MITCH, SL ;
DEFORREST, JM .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 28 :S115-S131
[8]  
LANZILLO JJ, 1985, J BIOL CHEM, V260, P4938
[9]   RADIOIMMUNOASSAY OF ANGIOTENSIN-II IN UNEXTRACTED PLASMA [J].
LIJNEN, PJ ;
AMERY, AK ;
FAGARD, RH ;
KATZ, FH .
CLINICA CHIMICA ACTA, 1978, 88 (02) :403-412
[10]  
LOWRY OH, 1951, J BIOL CHEM, V193, P265